Brokers Offer Predictions for VRCA Q4 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Brookline Capital Management issued their Q4 2025 earnings estimates for shares of Verrica Pharmaceuticals in a research note issued on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.03) per share for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.30 million.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Price Performance

NASDAQ VRCA opened at $0.54 on Friday. Verrica Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $11.41. The company has a market cap of $24.50 million, a P/E ratio of -0.29 and a beta of 1.44. The company has a 50-day moving average of $0.67 and a 200-day moving average of $1.08.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Invesco Ltd. purchased a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $32,000. Barclays PLC boosted its holdings in Verrica Pharmaceuticals by 404.6% in the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock worth $45,000 after acquiring an additional 25,130 shares during the period. Sanctuary Advisors LLC purchased a new position in Verrica Pharmaceuticals in the 3rd quarter worth approximately $87,000. Verition Fund Management LLC purchased a new position in Verrica Pharmaceuticals in the 3rd quarter worth approximately $89,000. Finally, Jane Street Group LLC boosted its holdings in Verrica Pharmaceuticals by 106.5% in the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock worth $101,000 after acquiring an additional 36,028 shares during the period. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.